Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > ONC Forecast

<< Previous

Bullboard Posts

Next >>

Post by Kswdeluxon May 27, 2022 2:16am

434 Views

Post# 34711193

ONC Forecast

https://www.tipranks.com/stocks/tse:onc/forecast

This website suggests an ONC share price of greater than $19 in 12 months.

This is the first I have seen such a rating. Does anyone know which analyst's reports they are referring to, and does anyone have copies to share?

I cannot find them.

I also assume there is the standard clause in those reports that those reports do not consider any partnerships or buyouts, but am curious.

Anyone ?